Aarti Pharmalabs Ltd Q2 FY2026 Concall Summary

Key Takeaways

• Revenue up, profits down: Standalone revenue grew 11% YoY to INR 417 crores, but EBITDA and PAT fell sharply as CDMO capacity absorption, API margin pressure, and a forex loss combined to compress earnings.
• CDMO is the growth engine, but it is eating capacity: CDMO-CMO is on track to exceed its 30–40% YoY growth target, yet its use of fungible plants is crowding out the higher-margin intermediate business, a drag that management says will ease over the next two quarters.
• API business hit a wall: Last year's large launches are now facing genericization and customer inventory overhang, pushing the segment into a "challenging" period; a recovery is expected only in the second half.
• Atali plant is live but not yet contributing: The new facility was inaugurated and trial batches have begun, but meaningful revenue and cost impacts will only start showing from Q4 and ramp through next year.
• What to watch next quarter: Whether the promised H2 EBITDA target of ~INR 300 crores holds once Atali costs begin hitting the P&L, and whether API volumes actually normalize as guided.

CDMO-CMO: The Growth Story and Its Near-Term Cost

• Growth exceeding guidance: The segment is on track to achieve and exceed the earlier estimated 30–40% YoY sales growth target, driven by new molecule commercializations, qualification with multiple API suppliers for innovator products, and increasing wallet share with existing customers.
• Six molecules moved from development to commercial phase in recent quarters, and seven to eight products have shifted into the commercialized space overall.
• The capacity trade-off is real: CDMO projects get first priority in fungible plants, which has reduced capacity available for the intermediate business and weighed on overall EBITDA. Management expects this impact to wind down over the coming two quarters as intermediate manufacturing capacity frees up.
• Revenue recognition is lumpy: For large orders spanning 8–10 in-house stages, plants are occupied over a full quarter but invoicing only occurs when goods are sold to the final customer, so profit accumulates with a lag and inventory builds in the interim.
• Pipeline strategy targets Phase-2 to Phase-3 molecules where the company can enter as a second-source supplier, with a focus on growable therapeutic areas.
• Business development push: A representative office has opened in Europe and the company plans to place a dedicated CDMO business development person in North America.

Rashesh Gogri: "One year here or there, but ultimately the numbers we will achieve and the numbers that we have targeted, we have mentioned earlier in our calls."

API Business: Margin Pressure and a Second-Half Recovery Bet

• The core problem is a post-launch hangover: Last year's large product launches carried good margins, but in their second year of genericization more players entered and margins compressed. The company had never before had launches large enough to materially drag the overall margin percentage.
• Customer inventory overhang: Buyers purchased roughly 1.5 years' worth of inventory during those launches, and now elevated stock levels plus new competition have created a "blip on a couple of projects."
• Sales mix skewed toward lower-margin APIs this quarter, adding to the segment's profitability pressure.
• Recovery timeline: Management expects the API business to normalize in the second half of this year, as intermediate manufacturing capacity currently absorbed by CDMO work gets freed up and new anti-cancer API launches begin contributing.
• Longer-term growth path: R&D and filings are complete for new lifestyle and anti-cancer APIs, with a few launches planned each year. Debottlenecking of the anti-cancer block, planned for late this year or early next, will support FY27 and FY28 launch targets.
• The segment should return to a growth trajectory next year, though the pace depends on how partners capture market share and secure API orders.

Atali Plant: Live, but the P&L Impact Is Still Ahead

• Operations began in the last week of Q2, so no material expense hit the quarter. Trial batches of a few products are underway for customer qualifications, with more products planned in the coming months.
• ~340 KL of capacity has been commercialized, and audits have started. Expenses for the commercialized block will begin appearing in the P&L from Q3 onward.
• Ramp-up will be gradual: Q4 will show some activity, but a couple of quarters of qualification work are still needed next year before a full ramp-up materializes. Meaningful revenue contribution is expected from FY27.
• The plant creates future headroom: Once ramped, Atali frees up space for more intermediate and CDMO manufacturing across the company's asset base.
• Cost clarity is coming: Management stated that next quarter's results will provide a "fair bit of clarity" on the expense run rate, while depreciation will increase in Q4 as more assets are capitalized toward year-end.

Xanthine: Stabilized Pricing, Capacity Headroom, and a Market-Share Ceiling

• Pricing has bottomed out and stabilized, though it has not moved significantly off the floor.
• Capacity expanded from 5,000 to 9,000 tons, with current operations running at approximately 500 metric tons per month after debottlenecking to 6,000 tons. Incremental capacity will be operationalized in phases.
• Market share is already ~25%, which management described as "very large." Further growth and share gains from that level are "going to be quite a task going forward." The capacity ramp is expected to play out over the next 2–3 years, with year one not expected to fill the expanded capacity.
• Both CDMO and Xanthine segments grew in H1 and are expected to continue growing in H2.

Rashesh Gogri: "We are taking up overall from the market share perspective also almost 25% of the market share, which is very large and now there to further grow and hold up, that is going to be quite a task going forward."

Margins, Costs, and the Forex Drag

• Standalone EBITDA fell to INR 75 crores from INR 85 crores YoY; consolidated EBITDA fell to INR 75 crores from INR 94 crores. PAT was hit by a INR 7.4 crore forex loss on foreign-currency long-term loans after the rupee depreciated more than INR 3 during the quarter.
• A INR 13 crore QoQ cost increase was driven partly by seasonality: Q2 is the weakest quarter for solar power generation, an impact of close to INR 3 crore. The remainder came from one-off manufacturing facility upgradation charges, particularly for Xanthine fungibility work for large customers, and spending to maintain operations during expansion.
• Forex strategy is deliberate: The company keeps foreign-currency loans unhedged because roughly 50% of the business is export, saving on hedging costs over the long term. The revaluation loss is a mark-to-market consequence of that structural choice.
• Management does not guide to an EBITDA margin percentage, only to absolute growth. It stated it is "not too worried about overall percentage EBITDA over top line," citing mix dependence.
• Ganesh Polychem posted a much lower loss than prior quarters, but the INR 3 crore dividend paid had a negative consolidation impact. The second half will remain soft; a return to reasonable profitability and 80–100% of FY25 levels is expected next year after plant modifications, cost reduction, and a site shift.

Rashesh Gogri: "Longer term we feel that looking at the nature of business and almost 50% export that we have as a strategy, company has decided to keep these loans Forex open. Because longer term otherwise we will have to hedge it and sell more dollars. And by this, we are saving the hedging cost."

Guidance & Commitments

Key Metrics